mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors

The Phosphatidylinositol 3-kinase/AKT/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients

(2015)   Oncotarget

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

(2015)   Oncotarget

Targeting mTOR for the treatment of AML. New agents and new directions.

(2015) Jessica K. Altman et al.   Oncotarget

mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes

(2011) Chi Kwan Tsang et al.   CELL CYCLE

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

(2011) Paige Yellen et al.   CELL CYCLE

The physiology and pathophysiology of rapamycin resistance

(2011) Philip A. Gruppuso et al.   CELL CYCLE

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway

(2010) Yan-Jie Zhang et al.   ANNALS OF SURGICAL ONCOLOGY

Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy

(2010) Andrew Y. Choo et al.   CELL CYCLE

Dual-targeting of mTOR and HSP90 for cancer therapy: Facing oncogenic feed-back-loops and acquired mTOR resistance

(2010) Oliver Stoeltzing   CELL CYCLE

New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways

(2010) A. Dasari et al.   CLINICAL CANCER RESEARCH

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer

(2009) Yan-Jie Zhang et al.   ANNALS OF SURGICAL ONCOLOGY

Rapamycin inhibits mTORC1, but not completely

(2009) Carson C. Thoreen et al.   Autophagy

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

Combined Inhibition of MEK and mTOR Signaling Inhibits Initiation and Progression of Colorectal Cancer

(2009) Yan-Jie Zhang et al.   CANCER INVESTIGATION

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets

(2009) Nahum Sonenberg et al.   CELL

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population

(2008) J Abubaker et al.   ONCOGENE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE